University Health Network, Princess Margaret Cancer Center
Welcome,         Profile    Billing    Logout  
 14 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, Rebecca
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT04467515: A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Terminated
1/2
13
Canada, US
CAM-H2
Precirix
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
12/23
12/23
S-C-PATHY, NCT06390657: Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors

Not yet recruiting
N/A
20
Europe
Planning CT, MRI
EBG MedAustron GmbH, The Princess Margaret Cancer Foundation
Cancer
12/25
12/25
Kim, John
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25

Download Options